Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezlotoxumab in Clostridioides difficile infection (BEYOND)
NCT05304715Phase 2Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bezlotoxumab in Clostridioides difficile infection (CDI), sponsored by Hellenic Institute for the Study of Sepsis. Started Apr 2022; status: completed.
02
Drugs
bezlotoxumab
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT05304715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304715.